Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A

The delivery of factor VIII (FVIII) through gene and/or cellular platforms has emerged as a promising hemophilia A treatment. Herein, we investigated the suitability of human placental cells (PLCs) as delivery vehicles for FVIII and determined an optimal FVIII transgene to produce/secrete therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Akabawy, Nadia, Rodriguez, Martin, Ramamurthy, Ritu, Rabah, Andrew, Trevisan, Brady, Morsi, Alshaimaa, George, Sunil, Shields, Jordan, Meares, Diane, Farland, Andrew, Atala, Anthony, Doering, Christopher B., Spencer, H. Trent, Porada, Christopher D., Almeida-Porada, Graça
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109377/
https://www.ncbi.nlm.nih.gov/pubmed/32258210
http://dx.doi.org/10.1016/j.omtm.2020.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109377/
https://www.ncbi.nlm.nih.gov/pubmed/32258210
http://dx.doi.org/10.1016/j.omtm.2020.03.001

Ejemplares similares